Human Genome Epidemiology Literature Finder
Records 1 - 19 (of 19 Records) |
Query Trace: Neutropenia and BRAF[original query] |
---|
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. Clinical colorectal cancer 2012 Mar 11 (1): 53-9. Carneiro Benedito A, Ramanathan Ramesh K, Fakih Marwan G, Krishnamurthi Smitha S, Lembersky Barry C, Stoller Ronald G, Lancaster Stewart L, Pinkerton Richard A, Crandall Theodore L, Schmotzer Amy R, Potter Douglas M, Bahary Nath |
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England) 2012 Jul 380 (9839): 358-65. Hauschild Axel, Grob Jean-Jacques, Demidov Lev V, Jouary Thomas, Gutzmer Ralf, Millward Michael, Rutkowski Piotr, Blank Christian U, Miller Wilson H, Kaempgen Eckhart, Martín-Algarra Salvador, Karaszewska Boguslawa, Mauch Cornelia, Chiarion-Sileni Vanna, Martin Anne-Marie, Swann Suzanne, Haney Patricia, Mirakhur Beloo, Guckert Mary E, Goodman Vicki, Chapman Paul |
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Feb 24 (2): 412-9. André T, Blons H, Mabro M, Chibaudel B, Bachet J-B, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, Aissat N, Cayre A, Penault-Llorca F, Laurent-Puig P, de Gramont A, |
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. The Lancet. Oncology 2013 Jul 14 (8): 733-40. Robert Caroline, Dummer Reinhard, Gutzmer Ralf, Lorigan Paul, Kim Kevin B, Nyakas Marta, Arance Ana, Liszkay Gabriella, Schadendorf Dirk, Cantarini Mireille, Spencer Stuart, Middleton Mark |
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Aug 24 (8): 2062-7. Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone |
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer research 2014 Apr 34 (4): 1967-73. Iwamoto Shigeyoshi, Hazama Shoichi, Kato Takeshi, Miyake Yasuhiro, Fukunaga Mutsumi, Matsuda Chu, Bando Hiroyuki, Sakamoto Junichi, Oba Koji, Mishima Hideyu |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. The Lancet. Oncology 2014 Mar 15 (3): 323-32. McArthur Grant A, Chapman Paul B, Robert Caroline, Larkin James, Haanen John B, Dummer Reinhard, Ribas Antoni, Hogg David, Hamid Omid, Ascierto Paolo A, Garbe Claus, Testori Alessandro, Maio Michele, Lorigan Paul, Lebbé Celeste, Jouary Thomas, Schadendorf Dirk, O'Day Stephen J, Kirkwood John M, Eggermont Alexander M, Dréno Brigitte, Sosman Jeffrey A, Flaherty Keith T, Yin Ming, Caro Ivor, Cheng Suzanne, Trunzer Kerstin, Hauschild Ax |
Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method. International journal of hematology 2018 Jul . Itamura Hidekazu, Ide Masaru, Sato Akemi, Sueoka-Aragane Naoko, Sueoka Eisaburo, Nishida Aya, Masunari Taro, Aoki Sadao, Takizawa Jun, Suzumiya Junji, Kimura Shin |
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Investigational new drugs 2019 Nov . Bendell Johanna C, Bischoff Helge G, Hwang Jimmy, Reinhardt Hans Christian, Zander Thomas, Wang Xuejing, Hynes Scott, Pitou Celine, Campbell Robert, Iversen Philip, Farrington Daphne L, Bell-McGuinn Katherine, Thomas Micha |
A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study). Journal of the anus, rectum and colon 2019 10 3 (3): 136-141. Yoshida Yoichiro, Yamada Takeshi, Matsuoka Hiroshi, Sonoda Hiromichi, Fukazawa Atsuko, Yoshida Hiroshi, Ishida Hideyuki, Hirata Keiji, Hasegawa Suguru, Sakamoto Kazuhiro, Otsuka Toshiaki, Koda Kei |
Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. International journal of cancer 2020 12 . Jensen Benny Vittrup, Schou Jakob V, Yilmaz Mette, Johannesen Helle H, Skougaard Kristin, Linnemann Dorte, Hogdall Estrid V, Larsen Finn O, Johansen Julia S, Pfeiffer Per, Nielsen Dorte |
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. Scientific reports 2021 7 11 (1): 14321. Fernández Montes Ana, Carmona-Bayonas Alberto, Jimenez-Fonseca Paula, Vázquez Rivera Francisca, Martinez Lago Nieves, Covela Rúa Marta, Cousillas Castiñeiras Antía, Gonzalez Villarroel Paula, De la Cámara Gómez Juan, Méndez José Carlos Méndez, Carriles Fernández Carmen, Sanchez Cánovas Manuel, Garcia García Tere |
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. The New England journal of medicine 2021 05 384 (19): 1810-1823. Tiacci Enrico, De Carolis Luca, Simonetti Edoardo, Capponi Monia, Ambrosetti Achille, Lucia Eugenio, Antolino Agostino, Pulsoni Alessandro, Ferrari Samantha, Zinzani Pier L, Ascani Stefano, Perriello Vincenzo M, Rigacci Luigi, Gaidano Gianluca, Della Seta Roberta, Frattarelli Natalia, Falcucci Paolo, Foà Robin, Visani Giuseppe, Zaja Francesco, Falini Brunange |
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. ESMO open 2021 Mar 6 (2): 100062. Sastre J, García-Alfonso P, Viéitez J M, Cano M T, Rivera F, Reina-Zoilo J J, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont M J, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López R L, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E, |
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial. European journal of cancer (Oxford, England : 1990) 2022 1 163 152-162. Wang Zhan, Qin Bao-Dong, Ye Chen-Yang, Wang Miao-Miao, Yuan Ling-Yan, Dai Wei-Ping, Sun Li, Liu Ke, Qin Wen-Xing, Jiao Xiao-Dong, Li Xing-Nan, Zang Yuan-She |
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. Biomedicines 2023 5 11 (5): . Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouz |
A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2024 1 . Emmanuelle Samalin, Thibault Mazard, Eric Assenat, Magali Rouyer, Christelle de la Fouchardière, Rosine Guimbaud, Denis Smith, Fabienne Portales, Marc Ychou, Antoine Adenis, Catherine Fiess, Evelyne Lopez-Crapez, Simon Thezen |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: